Igor Puzanov, MD, MSCI, FACP

Director, Early Phase Clinical Trials Program
Chief of Melanoma
Co-Leader, CCSG Experimental Therapeutics Program
Professor of Oncology, Department of Medicine
Roswell Park Cancer Institute
Professor of Medicine
Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo

Make an appointment online or call us at 1-800-Roswell Request an Appointment

Areas of Expertise: 
Early Phase Clinical Trials/Phase I Clinical Trials
Melanoma
Cancer Immunotherapy/Experimental Therapeutics
Precision Medicine

Biography

In my role as a Clinical Professor of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Professor of Medicine and Director of Early Phase Clinical Trials Program in the Department of Medicine at Roswell Park Cancer Institute, I am developing novel therapies for patients with cancer. This includes clinical trials from early pre-clinical phase through phase I/II/III with emphasis on combination of immune and targeted agents, novel drug design, including histology-agnostic trial development of targeted therapies. I also provide advice on regulatory requirements and necessary steps associated with advancing drugs, devices and imaging agents toward clinical trials in patients.

In my professional career, I have focused both on developing precision medicine agents as well as immunotherapies. In the first in human trial of PLX4032/vemurafenib our team has provided critical PK/PD data that led to the first in class/ first in human FDA-approved BRAF inhibitor. My interest and expertise in immunotherapy started in early 1990s with animal models of IL-2 and IL-15 cytokines and natural killer cell development, continued with high dose IL-2 studies and subsequently Phase I-III trials with both CTLA-4 and PD1/PDL-1 checkpoint inhibitors. Our team was instrumental in the development of talimogene laherparepvec, the first in human oncolytic virus therapy for patients with melanoma. Recently, we have explored immunotherapy combinations with targeted agents as well as combinations of oncolytic viruses with checkpoint inhibitors .

Our work was instrumental in several FDA approvals of breakthrough anti-cancer drugs (vemurafenib, dabrafenib+trametinib, vemurafenib+cobimetinib, pembrolizumab, talimogene laherparepvec) and resulted in almost 100 manuscripts, including New England Journal of Medicine, Lancet, Journal of Clinical Oncology, JAMA, Nature. I am a member of American Society of Medical Oncology, Society of Immunotherapy in Cancer, ACP, AACR and Society of Melanoma Research and serve as an editor and reviewer for several peer reviewed journals.

Background

Education and Training: 
1991 - MD, 3rd Faculty of Medicine, Charles University, Prague, Czechoslovakia
2007 - Master of Science in Clinical Investigation, Vanderbilt University, Nashville TN
Residency: 
2001 - UT Southwestern Medical Center at Dallas, Parkland Memorial Hospital
Fellowship: 
2005 - Vanderbilt University, Nashville TN
Board Certification: 
Medical Oncology
Internal Medicine